NCT07010822View on ClinicalTrials.gov

A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

740

Participants

Timeline

Start Date

December 8, 2025

Primary Completion Date

September 21, 2026

Study Completion Date

September 21, 2026

Conditions

Poliomyelitis

Interventions

BIOLOGICAL

nOPV2

nOPV2 will be administered at birth and Wk 14 of age depending on the study arm.

Trial Locations (1)

Unknown

icddr,b - Matlab Health Research Centre, Chāndpur

Sponsors

Lead Sponsor

Fidec Corporation

All Listed Sponsors

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Fidec Corporation

OTHER